Laura Stoppel - Jun 24, 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role: Director
Signature: /s/ Neha Krishnamohan, Attorney-in-Fact
Stock symbol: ARTV
Transactions as of: Jun 24, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/26/2025, 04:30 PM
Previous filing: Jun 5, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stoppel Laura	Director	C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO	/s/ Neha Krishnamohan, Attorney-in-Fact	2025-06-26	0001865119

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARTV	Director Stock Option (Right to Buy)	Award	$0	+13.8K		$0.00	13.8K	Jun 24, 2025	Common Stock	13.8K	$1.61	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.